Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: Case reports, review of the literature and implications for therapy

American Journal of Hematology

Volumn 61, Issue 3, 1999, Pages 205-208

  Jubelirer, Steven J ^a   Koenig, Beth A ^a   Bates, Mark C ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Abciximab; C7E3 Fab therapy; Glycoprotein; Heparin; Platelets; Thrombocytopenia

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR;

ARTICLE; BLEEDING; CASE REPORT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVASCULARIZATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ATHERECTOMY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RETROSPECTIVE STUDIES; STENTS; THROMBOCYTOPENIA;

EID: 0033052649     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199907)61:3<205::AID-AJH8>3.0.CO;2-9     Document Type: Article

References (11)

1. Anderson HV, Jordan RE, Weisman HF. Concept and clinical applications of platelet glycoprotein (GP) IIb/IIIa inhibition with abciximab (C7E# Fab; ReoPro) for the prevention of acute ischemic syndromes. Clin Appl Thrombosis Hemostasis 1997;3:256-266.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardivascular medicine. N Engl J Med 1995;332:1553.
3. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden death ischemic death and crescendo angina. Br Heart J 1985;53:363-373.
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
5. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tchenz JE, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. 1994;343:881-886.
6. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
7. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997;349:14209-14235.
8. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
9. Kereiakes DJ, Essell JH, Abbotsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia. Therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-1163.
10. Bednar B, Bednar RA, Cook JJ, Bolag DM, Chang CT, Gaul SL, McQueney PA, Egbertson MS, Hartman GD, Holahan MA, Lynch JJ, Gould RJ. Drug dependent antibodies against BP IIb/IIIa induced thrombocytopenia. Circulation 94(suppl I); I98-96.
11. Christopoulos CG and Machin SJ. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a Chimaeric antibody. Br J Maematol 1994;87:650-652.